Covance, with headquarters in Princeton, New Jersey, is one of the world's largest and most comprehensive drug development companies with annual revenues greater than $1.7 billion, global operations in 25 countries, and approximately 10,000 employees worldwide. Covance's diversified service portfolio, geographically dispersed operations, and broad customer base of hundreds of pharmaceutical and biotechnology companies provides the company with a very diverse revenue mix. In 2008, its top ten clients were less than 35% of sales and approximately 40% of revenues were from outside the United States.
Covance offers its pharmaceutical and biotechnology clients a broad array of services across all points in the drug development process - from preclinical safety assessment testing through clinical trial management. Approximately two-thirds of the company's revenues are derived from lab-based businesses, including its market leading central laboratory and toxicology services.
Information on Covance's products and services, recent press releases, and SEC filings can be obtained through its website at
